Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cancer patients want genetic testing to predict metastasis risk

03.06.2009
UCLA study shows results have little effect on mood, quality of life

If you had cancer and a genetic test could predict the risk of the tumor spreading aggressively, would you want to know – even if no treatments existed to help you?

An overwhelming majority of eye cancer patients would answer yes, according to a new UCLA study published in the June edition of the Journal of Genetic Counseling.

"Our goal was to explore what people with cancer want," explained Dr. Tara McCannel, director of the Ophthalmic Oncology Center at UCLA's Jules Stein Eye Institute and a Jonsson Comprehensive Cancer Center researcher. "We learned that patients want to know their prognosis, good or bad, even when there are no treatments at present for their condition."

The UCLA study surveyed 99 patients who had been diagnosed with ocular melanoma, which develops in the pigmented layers under the retina. Half of the patients had undergone localized radiation to shrink the tumor. The rest of the group also underwent radiation, but first had cells biopsied from their tumors. These cells were grown in culture and studied for a missing copy of chromosome 3 —the genetic marker most strongly linked to rapid metastatic disease.

Patients whose tumors contain the genetic marker have at least a 50 percent chance of death within five years, due to swift spreading of the tumor to the liver and other organs. Aggressive cases can result in blindness and death in as quickly as a year.

In the UCLA study, all patients were asked to evaluate their interest in receiving genetic testing results related to prognosis. A whopping 98 patients responded that they would have wanted predictive testing at the time of their treatment. Only one patient declined.

Additionally, 98 percent of the respondents stated that supportive counseling should be offered when patients receive their test results.

"We were surprised to see such a unanimous response," admitted McCannel. "We expected some patients would prefer not to know, but the numbers consistently said otherwise."

"People understand that no good treatment currently exists after their cancer spreads. Everyone wants to know what their risk is for metastasis," said coauthor Annette Stanton, UCLA professor of psychology, psychiatry and biobehavioral sciences. "If the risk is low, it's a huge relief and emotional burden off patients' shoulders. If the risk is high, it enables patients to plan arrangements for their family and finances and make the most of their time alive."

The UCLA survey also measured quality of life and depression symptoms in patients who received genetic test results and compared their rankings to those of untested patients.

"Regardless of their test result, all of the patients rated themselves about the same in terms of quality of life and emotional well-being," said Stanton, who is also a Jonsson Cancer Center member. "We hope that these findings reduce clinical resistance and pave the way for prognostic testing to become the standard of care in the management of ocular melanoma."

"The issue of genetic testing has been a huge source of clinical controversy," said McCannel. "People want information; they have a lot of things they still want to do in life. Knowing their prognosis offers a tool that helps them plan their lives. Our research demonstrates that it's valuable to give people these details, even when their disease is not presently treatable."

"Our results emphasize how important it is for patients to be treated in a full-service hospital research center that offers genetic testing and counseling and treats the whole patient, not just their disease," said Stanton.

Tumor biopsy also helps researchers search for key genes that play a role in aggressive metastasis, improving clinicians' ability to provide the best care.

"After analyzing the tumor specimens, we grow the biopsied cells in a culture dish and can add drugs to test which ones block cancer growth," said McCannel. "That is how we're going to beat this cancer. Developing drugs to target these genes will one day result in therapies and a cure."

The technique of fine-needle aspiration biopsy for collecting cancer cells from the living eye has been utilized at the Jules Stein Eye Institute since 2004, but adopted by only a handful of other ophthalmic centers in the nation.

Although rare, ocular melanoma is the most common eye cancer to strike adults. The National Eye Institute reports some 2,000 newly diagnosed cases of the cancer – roughly seven in 1 million people -- per year. The disease spans the age and ethnic spectrum, and is not hereditary.

The study's UCLA coauthors included first author Tammy Beran, Dr. Bradley Straatsma and Barry Burgess.

The research was supported by funding from the UCLA Jonsson Comprehensive Cancer Center.

Elaine Schmidt | EurekAlert!
Further information:
http://www.ucla.edu

More articles from Studies and Analyses:

nachricht Do microplastics harbour additional risks by colonization with harmful bacteria?
05.04.2018 | Leibniz-Institut für Ostseeforschung Warnemünde

nachricht Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Magnetic nano-imaging on a table top

20.04.2018 | Physics and Astronomy

Start of work for the world's largest electric truck

20.04.2018 | Interdisciplinary Research

Atoms may hum a tune from grand cosmic symphony

20.04.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>